The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: A systematic review and meta-analysis

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Chen, Jiao ^a   Fan, Fang ^a   Wang, J Y ^a   Long, Yang ^a   Gao, C L ^a   Stanton, R C ^b,c,d   Xu, Yong ^a  

^a Affiliated Hospital of Southwest Medical College   (China)

^b JOSLIN DIABETES CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; URINARY TRACT INFECTION;

DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; URINARY TRACT INFECTIONS;

EID: 85014928963     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44128     Document Type: Article

References (46)

1. The top 10 causes of death. http://who.int/mediacentre/factsheets/fs310/en (2013).
2. Gao, H. X., Regier, E. E., & Close, K. L. International Diabetes Federation World Diabetes Congress 2015. J Diabetes. 8, 300-302 (2016).
3. Diabetes: facts and figures. Brussels, Belgium: International Diabetes Federation. http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures (2014).
4. Orchard, T. J., et al. Association between 7 years of intensive treatment of type 1 diabetes and long-Term mortality. JAMA. 313, 45-53 (2015).
5. George, P., & McCrimmon, R. J. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med. 30, 179-188 (2013).
6. Liu, C., Wu, D., Zheng, X., Li, P., & Li, L. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-Analysis. Diabetes Technol Ther. 17, 142-148 (2015).
7. Libman, I. M., et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 314, 2241-2250 (2015).
8. Tafuri, K. S., Godil, M. A., Lane, A. H., & Wilson, T. A. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 5, 236-239 (2013).
9. Kuhadiya, N. D., et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 19, 963-967 (2013).
10. Garg, S. K., et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigatorinitiated, double-blind, randomized, placebo controlled trial. Endocr Pract. 19, 19-28 (2013).
11. Miller, K. M., et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 38, 971-978 (2015).
12. Idris, I., & Donnelly, R. Sodium-glucose co-Transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 11, 79-88 (2009).
13. Yang, X. P., Lai, D., Zhong, X. Y., Shen, H. P., & Huang, Y. L. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-Analysis. Eur J Clin Pharmacol. 70, 1149-1158 (2014).
14. Baker, W. L., et al. Effects of sodium-glucose co-Transporter 2 inhibitors on blood pressure: a systematic review and meta-Analysis. J Am Soc Hypertens. 8, 262-275 (2014).
15. Monami, M., Nardini, C., & Mannucci, E. Efficacy and safety of sodium glucose co-Transport-2 inhibitors in type 2 diabetes: a metaanalysis of randomized clinical trials. Diabetes Obes Metab. 16, 457-466 (2014).
16. Liakos, A., et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-Analysis. Diabetes Obes Metab. 16, 984-993 (2014).
17. Matthias, Oelze, et al. The sodium-glucose co-Transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PloS One. 9, 112394, 10.1371/journal. pone.0112394 (2014).
18. Cheng, S. T., Chen, L., Li, S. Y., Mayoux, E., & Leung, P. S. The Effects of Empagliflozin, an sglt2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes. PloS One. 11, 0147391, 10.1371/journal.pone.0147391 (2016).
19. Henry, R. R., et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes:a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 38, 421-429 (2015).
20. Sands, A. T., et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 38, 1181-1188 (2015).
21. Henry, R. R., Thakkar, P., Tong, C., Polidori, D., & Alba, M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 38, 2258-2265 (2015).
22. Pieber, T. R., et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes:4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 17, 928-935 (2015).
23. Cherney, D. Z., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 129, 587-597 (2014).
24. Cherney, D. Z., et al. The effect of empagliflozin on arterial stiffness and heart rate varia-bility in subjects with uncomplicated type 1 diabetes mellitus. Cardio vasc Diabetol. 13, 28 (2014).
25. Perkins, B. A., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week openlabel proof-of-concept trial. Diabetes Care. 37, 1480-1483 (2014).
26. Tamez, H. E., Tamez, A. L., Garza, L. A., Hernandez, M. I., & Polanco, A. C. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 14, 78 (2015).
27. Argento, N. B., & Nakamura, K. Glycemic effects of sglt2 inhibitor canagliflozin in type 1 diabetes using DEXCOMG4 PLATINUM CGM. Endocr Pract. 22, 315-322 (2016).
28. Perkins, B. A., et al. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. PLoS One. 10, 0141085, 10.1371/journal.pone.0141085 (2015).
29. American Diabetes Association. Diagnosis and classifications of diabetes mellitus. Diabetes Care. 37, S81-90 (2014).
30. Higgins, J. P. T., & Green, S. The Cochrane Collaboration network http://handbook.cochrane.org (2011).
31. Zinman, B., et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 373, 2117-2128 (2015).
32. Petes, A. L., et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotrans-porter 2 inhibition. Diabetes Care. 38, 1687-1693 (2015).
33. Erondu, N., Desai, M., Ways, K., & Meininger, G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 38, 1680-1686 (2015).
34. Taylor, S. I., Blau, J. E., & Rother, K. I. SGLT-2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 100, 2849-2852 (2015).
35. Perilli, G., Saraceni, C., Daniels, M. N., & Ahmad, A. Diabetic ketoacidosis: a review and update. Curr Emerg Hosp Med Rep. 1, 10-17 (2013).
36. Burke, K. R., Schumacher, C. A., & Harpe, S. E. SGLT2 Inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy., 10.1002/phar.1881 (2016).
37. Tang, H., et al. Sodium-glucose co-Transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-Analysis of randomized controlled trials. Diabetes Obes Metab. 19, 142-147 (2017).
38. Cohen, J. J., Berglund, F., & Lotspeich, W. D. Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am J Physiol. 184, 91-96 (1956).
39. Rosenstock, J., & Ferrannini, E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 38, 1638-1642 (2015).
40. Kibbey, R. G. SGLT-2 inhibition and glucagon: cause for alarm? Trends Endocrinol Metab. 26, 337-338 (2015).
41. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. U.S. Food and Drug Administration http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm (2016).
42. Yehuda, Handelsman, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 22, 753-762 (2016).
43. Tang, H., Li, D., Wang, T., Zhai, S., & Song, Y. Effect of sodium-glucose cotransporter 2 inhibitors on dia\betic ketoacidosis among patients with type 2 diabetes: a meta-Analysis of randomized controlled trials. Diabetes Care. 39, 123-124 (2016).
44. Yamout, H., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 40, 64-74 (2014).
45. Heerspink, H. J., et al. Canagliflozin slows progression of renal function decline independent-ly of glycemic effects. J Am Soc Nephrol. 28, 368-375 (2017).
46. Wanner, C., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 375, 323-34 (2016).